Nivolumab
CAS 946414-94-4Biologic
Overview
Nivolumab is a human IgG4 monoclonal antibody that acts as a checkpoint inhibitor, specifically targeting the programmed death-1 (PD-1) receptor to enhance anti-tumor immunity. It is primarily used in the treatment of various cancers, including metastatic melanoma, non-small cell lung cancer, and renal cell carcinoma.
Therapeutic areas
OncologyImmunology
Verified Supplier Partner
Do you supply Nivolumab? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.